ABCL
AbCellera Biologics Inc.
NASDAQ · Healthcare · Biotechnology · CA
$11.43
−1.21%Aug 11, 2026, 20:01 UTC
AbCellera announced a proposed public offering of common stock and pre-funded warrants to raise capital.
Aug 10, 2026, 11:13 UTC
AbCellera announced on Monday that its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial.
Aug 6, 2026, 01:36 UTC
AbCellera Biologics Inc. reported a Q2 2026 loss of $0.18 per share, missing the Zacks Consensus Estimate of a $0.17 loss and wider than the $0.12 loss a year ago.
Source:Jul 29, 2026, 11:00 UTC
AbCellera announced a collaboration with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions.
Source:Jul 6, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Lynn Seely, M.D. as a Class III director, effective June 30, 2026.
Jun 17, 2026, 11:43 UTC
Jazz Pharmaceuticals and AbCellera entered into a research collaboration and licensing agreement to develop T-cell engaging multispecific antibodies for cancer.
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.